A Phase 1, Open-Label Adaptive Design Study To Evaluate PDE10 Enzyme Occupancy As Measured By Positron Emission Tomography (PET) Following Single Oral Dose Administration Of PF-02545920 In Healthy Male Subjects

Trial Profile

A Phase 1, Open-Label Adaptive Design Study To Evaluate PDE10 Enzyme Occupancy As Measured By Positron Emission Tomography (PET) Following Single Oral Dose Administration Of PF-02545920 In Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 01 May 2017

At a glance

  • Drugs Mardepodect (Primary)
  • Indications Huntington's disease; Schizophrenia
  • Focus Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 09 Nov 2014 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 07 Oct 2014 Planned number of patients changed from 12 to 15, as reported by ClinicalTrials.gov.
    • 07 Jul 2014 Planned End Date changed from 1 Aug 2014 to 1 Nov 2014, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top